Showing 15,181 - 15,200 results of 64,515 for search '(( 5 ((ppm decrease) OR (((nn decrease) OR (a decrease)))) ) OR ( 5 point decrease ))', query time: 1.01s Refine Results
  1. 15181

    Table_3_CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson’s disease.xlsx by Rui Wang (52434)

    Published 2023
    “…According to KEGG pathways enrichment analysis, the methylated genes CACNA1B (hypomethylated), CREB5 (hypermethylated), GNB4 (hypomethylated), and PPP2R5A (hypomethylated) were enriched in the dopaminergic synapse pathway. …”
  2. 15182

    Table_3_CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson’s disease.xlsx by Rui Wang (52434)

    Published 2023
    “…According to KEGG pathways enrichment analysis, the methylated genes CACNA1B (hypomethylated), CREB5 (hypermethylated), GNB4 (hypomethylated), and PPP2R5A (hypomethylated) were enriched in the dopaminergic synapse pathway. …”
  3. 15183

    Table_1_CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson’s disease.doc by Rui Wang (52434)

    Published 2023
    “…According to KEGG pathways enrichment analysis, the methylated genes CACNA1B (hypomethylated), CREB5 (hypermethylated), GNB4 (hypomethylated), and PPP2R5A (hypomethylated) were enriched in the dopaminergic synapse pathway. …”
  4. 15184

    Table_2_CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson’s disease.docx by Rui Wang (52434)

    Published 2023
    “…According to KEGG pathways enrichment analysis, the methylated genes CACNA1B (hypomethylated), CREB5 (hypermethylated), GNB4 (hypomethylated), and PPP2R5A (hypomethylated) were enriched in the dopaminergic synapse pathway. …”
  5. 15185

    Table_1_CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson’s disease.doc by Rui Wang (52434)

    Published 2023
    “…According to KEGG pathways enrichment analysis, the methylated genes CACNA1B (hypomethylated), CREB5 (hypermethylated), GNB4 (hypomethylated), and PPP2R5A (hypomethylated) were enriched in the dopaminergic synapse pathway. …”
  6. 15186
  7. 15187
  8. 15188
  9. 15189
  10. 15190

    Table_1_An Immune Gene-Related Five-lncRNA Signature for to Predict Glioma Prognosis.DOCX by Xinzhuang Wang (9691811)

    Published 2020
    “…Coexpressed lncRNAs were analyzed to generate a model of lncRNAs and immune-related genes. We analyzed the model using survival and Cox regression. …”
  11. 15191
  12. 15192
  13. 15193

    DataSheet3_LAMP5 may promote MM progression by activating p38.ZIP by Yan Chen (4308)

    Published 2023
    “…Western blotting assay also found more expression of LAMP5 in NDMM than in HD. Patients with high LAMP5 expression have a higher DS (Durie-Salmon) stage and worse prognosis. …”
  14. 15194
  15. 15195

    Data Sheet 1_Diethyl butylmalonate attenuates cognitive deficits and depression in 5×FAD mice.docx by Lai Yuan (20136422)

    Published 2024
    “…In addition, DBM decreased the accumulation of microglia and downregulated neuroinflammation in the hippocampus and amygdala of 5×FAD mice.…”
  16. 15196
  17. 15197

    DataSheet1_LAMP5 may promote MM progression by activating p38.ZIP by Yan Chen (4308)

    Published 2023
    “…Western blotting assay also found more expression of LAMP5 in NDMM than in HD. Patients with high LAMP5 expression have a higher DS (Durie-Salmon) stage and worse prognosis. …”
  18. 15198

    DataSheet4_LAMP5 may promote MM progression by activating p38.ZIP by Yan Chen (4308)

    Published 2023
    “…Western blotting assay also found more expression of LAMP5 in NDMM than in HD. Patients with high LAMP5 expression have a higher DS (Durie-Salmon) stage and worse prognosis. …”
  19. 15199
  20. 15200

    Comparison of 10 emerging SARS-CoV-2 Variants: infectivity, animal tropism, and antibody neutralization by Jianhui Nie (8975930)

    Published 2021
    “…However, the resistance to neutralization by convalescent serum or vaccines was mainly caused by the E484K mutation, while the neutralization of E484K-carrying variants was decreased by 1.1–6.2-fold. <a>The convalescent serum from B.1.1.7- and B.1.351-infected patients neutralized the variants themselves better than other SARS-CoV-2 variants.…”